Safety and Efficacy of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)

Brief description of study

This study is being done to learn more about AMG 570 in people with systemic lupus erythematosus (SLE). The purpose of the study is to evaluate safe and effective doses of AMG 570 for the treatment of active SLE in patients who are not responding to the current standard of care. In autoimmune diseases such as SLE, it is thought that excessive inflammation is caused by the over-activity of two particular immune cells: T cells and B cells. Many treatments for autoimmune diseases work by targeting and blocking either T cells or B cells. But AMG 570 is designed to block both cell types, by targeting and blocking two molecules important for T cell and B cell over-activity, named ICOSL and BAFF. In previous studies, this dual-target approach has been found to be more effective than only targeting one cell type.


Clinical Study Identifier: s19-01353
ClinicalTrials.gov Identifier: NCT04058028
Principal Investigator: Amit Saxena.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.